HPS-146 - Comparison of cancer risks associated with JAK inhibitor and TNF inhibitor treatment in patients with Rheumatoid Arthritis: A systematic review and meta-analysis of real-world cohort studies

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-146
• By: FUYU, Yang (Changhua Christian Medical Foundation Yuanlin Christian Hospital, China Taiwan)
• Co-author(s): Ms Yang Fuyu (Changhua Christian Medical Foundation Yuanlin Christian Hospital, No. 456, Juguang Rd., Yuanlin City, Changhua County 510 , Taiwan (r.o.c.), China Taiwan)
  Mr Hung Cheng Hsien (Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, No. 6, Lugong Rd., Lukang Township, Changhua County , Taiwan (R.O.C.), China Taiwan)
  Mr Wu Min You (School of Medicine, Chung Shan Medical University, Taichung, Taiwan, No. 110, Sec. 1, Jianguo N. Rd., South Dist., Taichung City, Taiwan (R.O.C.), China Taiwan)
  Mr Wu Yao Cheng (School of Medicine, Chung Shan Medical University, Taichung, Taiwan, No. 110, Sec. 1, Jianguo N. Rd., South Dist., Taichung City, Taiwan (R.O.C.), China Taiwan)
  
• Abstract:

  Introduction:
  Concerns have been raised regarding the potential increased cancer risk associated with the use of Janus kinase inhibitors (JAKi) compared to anti-tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA), although findings from published cohort studies remain inconsistent. To address this, we performed a..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login